Abstract:BACKGROUND:The highly heterogeneous, complex pathological histology, and clinical phenotype in bladder cancer (BC) plague the prognostic management of BC to the present day.METHODS:This study was conducted using single-cell sequencing data from the gene expression omnibus (GEO) database (GSE135337). A descending, annotated analysis was performed to identify the cell types contributing to BC aggressiveness. BC cell sequencing data from The Cancer Genome Atlas (TCGA) database were then combined with univariate, least absolute shrinkage and selection operator (LASSO), multivariate COX regression analysis to identify biomarkers of BC prognosis to construct a BC. We identified biomarkers of BC prognosis to construct a prognostic risk guidance system for BC. The feedback of patients in different risk strata to immunotherapy was analyzed. Finally, the regulation of prognostic genes on cancer cell activity was verified in vitro by Western blot and cell counting kit-8 (CCK8) assays.RESULTS:Macrophages specifically expressing CD68 in BC were the cell type with the highest AUCell score, and CD68 was the biomarker of Tumor-associated macrophages (TAMs). CD68 macrophages were potentially the critical cell type in the aggressive BC subtype. Through univariate, LASSO, multivariate COX-based regression analysis. CTSS, GMFG, ANXA5, GSN, SLC2A3, and FTL were authenticated as prognostic biomarkers (p < 0.05) and composed the Risk Score. Patients in the low-risk group showed an excellent survival advantage (p < 0.01) and immunotherapy feedback. Additionally, inhibition of GSN expression decreased EMT activity to inhibit bladder cancer cell viability.CONCLUSION:In conclusion, this study provided feedback on the immune cell types associated with aggressiveness in BC. Importantly, a prognostic management system for BC was created based on the genes involved, providing more insight into the aggressive pathological phenotype as well as the prognosis of BC.

Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies

Tumor-Associated Macrophages in Tumor Immunity (vol <i>11</i>, <i>583084</i>, <i>2020</i>)

Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy

Targeting Tumor-Associated Macrophages As an Antitumor Strategy.

Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review)

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Optimization of BCG Therapy Targeting Neutrophil Extracellular Traps, Autophagy, and Mirnas in Bladder Cancer: Implications for Personalized Medicine

Targeting tumor-associated macrophages for cancer treatment

Single-cell Sequencing Data Reveals Aggressive CD68-type Macrophages and Prognostic Models in Bladder Cancer.

The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy

Tumor-Associated Macrophages: Recent Insights and Therapies

Tumor-Associated Macrophages: A Potential Target For Cancer Therapy

Tumor-associated macrophages: Potential therapeutic targets and diagnostic markers in cancer

Tumor-associated macrophages: an accomplice in solid tumor progression

Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer

Targeting tumor-associated macrophages to synergize tumor immunotherapy

Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer

Anti-tumour strategies aiming to target tumour-associated macrophages.

Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma

Immunosuppressive Tumor-Associated Macrophages Expressing Interlukin-10 Conferred Poor Prognosis and Therapeutic Vulnerability in Patients with Muscle-Invasive Bladder Cancer.

Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression